AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38872204 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention group (personalized, supervised, hybrid intervention with group meetings and individual sessions)
Number of subjects: 1210
Study 38872204 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity intervention group (bi-monthly online lifestyle-related health advice)
Number of subjects: 1210
Study 38872214 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-method intervention in primary care
Number of subjects: 0
Study 38872480 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + carboplatin and paclitaxel (CP)
Number of subjects: 100
Study 38872480 — intervention group
Group type: COMPARATOR
Intervention: Placebo + carboplatin and paclitaxel (CP)
Number of subjects: 100
Study 38872480 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + CP
Number of subjects: 100
Study 38872480 — intervention group
Group type: COMPARATOR
Intervention: Placebo + CP
Number of subjects: 100
Study 38872812 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality Digital Therapeutics (Reality DTx) - 6-week AR exergaming intervention, default five sessions/week of 30 active minutes/session
Number of subjects: 24
Study 38872812 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 24
Study 38872830 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA/MAGE-A4 assays validation for TCR T cell therapies
Number of subjects: 6606
Study 38872830 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A4 prevalence in clinical trial enrollment
Number of subjects: 6606
Study 38872830 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A4 prevalence by tumor type
Number of subjects: 6606
Study 38872830 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariates analysis
Number of subjects: 6606
Study 38872994 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/day
Number of subjects: 14
Study 38872994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 38873124 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab-cilgavimab)
Number of subjects: 0
Study 38873124 — intervention group
Group type: EXPERIMENTAL
Intervention: Authentic- and lentiviral pseudovirus-based neutralisation assays
Number of subjects: 0
Study 38873183 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable e-cigarettes for 8 weeks
Number of subjects: 120
Study 38873183 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 120
Study 38873265 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest myocardial blood flow (MBF)
Number of subjects: 92
Study 38873265 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial work efficiency (MWE)
Number of subjects: 92
Study 38873265 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) systolic dysfunction
Number of subjects: 92
Study 38873632 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 6 mg (UPA6)
Number of subjects: 185
Study 38873632 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 11 mg (UPA11)
Number of subjects: 185
Study 38873632 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 22 mg (UPA22)
Number of subjects: 185
Study 38873632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 185
Study 38873634 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic oxytocin (OXY) - 10UI intramuscularly within 5 minutes from childbirth
Number of subjects: 256
Study 38873634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TRAN) - 1-g slow intravenous infusion within 5 minutes from childbirth
Number of subjects: 256
Study 38873634 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 256
Study 38873657 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief quitline intervention
Number of subjects: 0
Study 38873657 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 38873723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) plus standard care
Number of subjects: 507
Study 38873723 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care alone)
Number of subjects: 507
Study 38873885 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin (500 mg)
Number of subjects: 2013
Study 38873885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study 38873891 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 85
Study 38873891 — intervention group
Group type: COMPARATOR
Intervention: Control (no teduglutide)
Number of subjects: 85
Study 38873934 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib at 550 mg/m2 (maximum 960 mg/dose) orally twice daily for 28-day cycles
Number of subjects: 4
Study 38873934 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib
Number of subjects: 4
Study 38874333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (IPI)
Number of subjects: 32
Study 38874333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO)
Number of subjects: 32
Study 38874333 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ipilimumab and Nivolumab (IPI + NIVO)
Number of subjects: 32
Study 38874333 — intervention group
Group type: COMPARATOR
Intervention: Control (Standard treatment)
Number of subjects: 32
Study 38874488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficiently active physical activity (≥600 MET-min/week) and qualified dietary quality (≥60)
Number of subjects: 3007
Study 38874488 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficiently active physical activity (>0 MET-min/week) and qualified dietary quality (≥60)
Number of subjects: 3007
Study 38874505 — intervention group
Group type: EXPERIMENTAL
Intervention: Bankart repair with remplissage (REMP)
Number of subjects: 108
Study 38874505 — intervention group
Group type: COMPARATOR
Intervention: Isolated Bankart repair (NO REMP)
Number of subjects: 108
Study 38874529 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP MRI metrics
Number of subjects: 271
Study 38874529 — intervention group
Group type: COMPARATOR
Intervention: ADC
Number of subjects: 271
Study 38874618 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1RA
Number of subjects: 92
Study 38874618 — intervention group
Group type: COMPARATOR
Intervention: SGLT2 inhibitor
Number of subjects: 92
Study 38874618 — intervention group
Group type: COMPARATOR
Intervention: Neither therapy
Number of subjects: 92
Study 38874697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Number of subjects: 97
Study 38874697 — intervention group
Group type: COMPARATOR
Intervention: Ferric carboxymaltose
Number of subjects: 97
Study 38874739 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC 200 mg BID
Number of subjects: 1039
Study 38874739 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 50 or 100 mg four times a day
Number of subjects: 1039
Study 38874739 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 100 mg BID
Number of subjects: 1039
Study 38874739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1039
Study 38874763 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Number of subjects: 48
Study 38874763 — intervention group
Group type: COMPARATOR
Intervention: Unstructured social interviewing (placebo)
Number of subjects: 48
Study 38874763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 38874776 — intervention group
Group type: EXPERIMENTAL
Intervention: dPTFE group (tooth extraction and alveolar ridge preservation using intentionally exposed dPTFE membrane)
Number of subjects: 44
Study 38874776 — intervention group
Group type: COMPARATOR
Intervention: USH group (tooth extraction and unassisted socket healing)
Number of subjects: 44
Study 38874776 — intervention group
Group type: EXPERIMENTAL
Intervention: dPTFE group
Number of subjects: 44
Study 38875108 — intervention group
Group type: EXPERIMENTAL
Intervention: Repotrectinib (Augtyro)
Number of subjects: 127
Study 38875119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (BA) plus GemCis (gemcitabine 1000 mg/m2 + cisplatin 25 mg/m2 on days 1 and 8 every 3 weeks for 8 cycles)
Number of subjects: 297
Study 38875119 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus GemCis (gemcitabine 1000 mg/m2 + cisplatin 25 mg/m2 on days 1 and 8 every 3 weeks for 8 cycles)
Number of subjects: 297
Study 38875119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (BA) plus GemCis
Number of subjects: 297
Study 38875119 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus GemCis
Number of subjects: 297
Study 38875120 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) of the motor cortex
Number of subjects: 0
Study 38875120 — intervention group
Group type: EXPERIMENTAL
Intervention: New algorithm for predicting response to rTMS
Number of subjects: 0
Study 38875121 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting dexamethasone viscous gel delivered by transforaminal injection
Number of subjects: 0
Study 38875121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38875111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole (40 mg daily)
Number of subjects: 4821
Study 38875111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4821
Study 38875279 — intervention group
Group type: EXPERIMENTAL
Intervention: LUNA treatment delivered twice weekly for 10 weeks via videoconferencing (Zoom)
Number of subjects: 28
Study 38875279 — intervention group
Group type: EXPERIMENTAL
Intervention: LUNA treatment
Number of subjects: 28
Study 38875292 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS program (health education program delivered via SMS)
Number of subjects: 7890
Study 38875292 — intervention group
Group type: COMPARATOR
Intervention: Non-SMS group (control)
Number of subjects: 7890
Study 38875501 — intervention group
Group type: EXPERIMENTAL
Intervention: German ED Senior AID tool
Number of subjects: 1010
Study 38875501 — intervention group
Group type: COMPARATOR
Intervention: All patients
Number of subjects: 1010
Study 38875516 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Stroke Center (CSC)
Number of subjects: 1961
Study 38875516 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer from TSC/PSC to CSC
Number of subjects: 1961
Study 38875516 — intervention group
Group type: COMPARATOR
Intervention: Telestroke Center (TSC) / Primary Stroke Center (PSC)
Number of subjects: 1961
Study 38875550 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-enabled screening tool
Number of subjects: 29
Study 38875564 — intervention group
Group type: EXPERIMENTAL
Intervention: App feature use patterns
Number of subjects: 133
Study 38875564 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model including SML-predicted probabilities
Number of subjects: 133
Study 38875579 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized automatic messaging system (PAMS) using SMS text messaging and data integration into clinical workflows
Number of subjects: 0
Study 38875579 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) models using weekly and daily DPP data sets (328,821 and 704,242 records)
Number of subjects: 0
Study 38875579 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with any activity in the dDPP in the last 7 days
Number of subjects: 0
Study 38875579 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent profile analysis after 2 weeks of engagement
Number of subjects: 0
Study 38875579 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning methods for tailoring messaging interventions
Number of subjects: 0
Study 38875682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinematographic recordings during maximum flexion and extension
Number of subjects: 11
Study 38875682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinematographic recordings during maximum extension
Number of subjects: 11
Study 38875880 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based addiction treatment (OBAT)
Number of subjects: 1988
Study 38875880 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1988
Study 38876123 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system
Number of subjects: 9129
Study 38876123 — intervention group
Group type: COMPARATOR
Intervention: Radiologists using PI-RADS (2.1)
Number of subjects: 9129
Study 38876129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained lupus low disease activity state (LLDAS)
Number of subjects: 3449
Study 38876129 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission
Number of subjects: 3449
Study 38876132 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-Gy stereotactic radiotherapy (SRT)
Number of subjects: 411
Study 38876132 — intervention group
Group type: COMPARATOR
Intervention: Sham SRT
Number of subjects: 411
Study 38876137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (34-35°C)
Number of subjects: 365
Study 38876137 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36·5-37·5°C)
Number of subjects: 365
Study 38876630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization technique plus conventional physiotherapy
Number of subjects: 40
Study 38876630 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 40
Study 38876630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 38876647 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy interventions (MTIs) including passive joint mobilisation and soft tissue manipulation, administered for eight weekly 30-min sessions.
Number of subjects: 15
Study 38876647 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy interventions (MTIs)
Number of subjects: 15
Study 38876657 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises combined with NMES (ESG)
Number of subjects: 34
Study 38876657 — intervention group
Group type: COMPARATOR
Intervention: Exercises only (ExG)
Number of subjects: 34
Study 38876748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined technique (stent retrievers plus contact aspiration)
Number of subjects: 521
Study 38876748 — intervention group
Group type: COMPARATOR
Intervention: Contact aspiration alone
Number of subjects: 521
Study 38876800 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block with parasternal block
Number of subjects: 58
Study 38876800 — intervention group
Group type: COMPARATOR
Intervention: Parasternal block with epigastric exit sites of chest drains receiving surgical infiltration of local anesthetic
Number of subjects: 58
Study 38877036 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPEC10V
Number of subjects: 416
Study 38877036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 38877077 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby program (Cognitive Behavior Therapy)
Number of subjects: 796
Study 38877325 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbilirubinemia requiring phototherapy
Number of subjects: 1526
Study 38877325 — intervention group
Group type: COMPARATOR
Intervention: No hyperbilirubinemia (Control)
Number of subjects: 1526
Study 38877446 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 40
Study 38877446 — intervention group
Group type: COMPARATOR
Intervention: Freeze-dried bone allograft (FDBA)
Number of subjects: 40
Study 38877450 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection rectopexy (L-RRP) with mesh-sacrocolpopexy (L-SCP) using synthetic mesh (SM)
Number of subjects: 44
Study 38877450 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection rectopexy (L-RRP) with mesh-sacrocolpopexy (L-SCP) using biological mesh (BM)
Number of subjects: 44
Study 38877464 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin membrane + NanoBone
Number of subjects: 40
Study 38877464 — intervention group
Group type: COMPARATOR
Intervention: Platelet Rich Fibrin membrane
Number of subjects: 40
Study 38877477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (FBSF)
Number of subjects: 30
Study 38877533 — intervention group
Group type: EXPERIMENTAL
Intervention: remimazolam
Number of subjects: 696
Study 38877533 — intervention group
Group type: COMPARATOR
Intervention: propofol-based TIVA
Number of subjects: 696
Study 38877571 — intervention group
Group type: COMPARATOR
Intervention: Haemoglobin values < 7.5 g/dL
Number of subjects: 1590
Study 38877571 — intervention group
Group type: COMPARATOR
Intervention: Haemoglobin values between 7.5-9.5 g/dL
Number of subjects: 1590
Study 38877571 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of haemoglobin value
Number of subjects: 1590
Study 38877571 — intervention group
Group type: COMPARATOR
Intervention: Anaemia (Hb < 9.5 g/dL)
Number of subjects: 1590
Study 38877595 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS group (20 min of 2.0-mA direct current to frontal lobes)
Number of subjects: 34
Study 38877595 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS group (30 s of stimulation to the frontal lobes)
Number of subjects: 34
Study 38877608 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Test-and-Exercise home-based exercise program (8 weeks, once per week with a physiotherapist, twice per week with caregiver or independently)
Number of subjects: 12
Study 38877716 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NaF mouth rinse (226 ppm F)
Number of subjects: 20
Study 38877716 — intervention group
Group type: COMPARATOR
Intervention: Calcium prerinse followed by 0.05% NaF mouth rinse
Number of subjects: 20
Study 38877762 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG + FTC/TAF
Number of subjects: 340
Study 38877762 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 340
Study 38877777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL) treatment
Number of subjects: 177
Study 38877972 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg once daily
Number of subjects: 274
Study 38877972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 38877993 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament polydioxanone barbed suture, MONOFIX
Number of subjects: 30
Study 38878007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 1222
Study 38878007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1222
Study 38878009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 202
Study 38878009 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 202
Study 38878063 — intervention group
Group type: EXPERIMENTAL
Intervention: No intraabdominal drains
Number of subjects: 71
Study 38878063 — intervention group
Group type: COMPARATOR
Intervention: Intraabdominal drains
Number of subjects: 71
Study 38878121 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 1057
Study 38878121 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 1057
Study 38878121 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo patients
Number of subjects: 1057
Study 38878121 — intervention group
Group type: EXPERIMENTAL
Intervention: DRF-treated patients after re-baselining
Number of subjects: 1057
Study 38878121 — intervention group
Group type: COMPARATOR
Intervention: Patients not re-baselined
Number of subjects: 1057
Study 38878145 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib population pharmacokinetic models
Number of subjects: 11
Study 38878175 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial PET scans at 5, 15, 30, 45, 60, and 120 min after intervention
Number of subjects: 21
Study 38878207 — intervention group
Group type: EXPERIMENTAL
Intervention: TLD-1 (pegylated liposomal doxorubicin)
Number of subjects: 30
Study 38878209 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg QD from Day 15 to Day 21
Number of subjects: 11
Study 38878209 — intervention group
Group type: COMPARATOR
Intervention: Encorafenib 450 mg QD from Day 1
Number of subjects: 11
Study 38878209 — intervention group
Group type: COMPARATOR
Intervention: Binimetinib 45 mg BID from Day 1
Number of subjects: 11
Study 38878236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG laser + Platelet-Rich Plasma (PRP)
Number of subjects: 40
Study 38878236 — intervention group
Group type: COMPARATOR
Intervention: Microneedling + Platelet-Rich Plasma (PRP)
Number of subjects: 40
Study 38878337 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based ACT combined with Treatment as Usual (iACT + TAU)
Number of subjects: 103
Study 38878337 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 103
Study 38878692 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured active play intervention
Number of subjects: 18
Study 38878794 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2816 (4-week interval)
Number of subjects: 1449
Study 38878794 — intervention group
Group type: COMPARATOR
Intervention: AZD1222
Number of subjects: 1449
Study 38878794 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2816 (12-week interval)
Number of subjects: 1449
Study 38878794 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222-AZD2816
Number of subjects: 1449
Study 38878794 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2816 (4-week)
Number of subjects: 1449
Study 38878794 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2816 (12-week)
Number of subjects: 1449
Study 38878969 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of intraplaque hemorrhage (IPH)
Number of subjects: 89
Study 38878969 — intervention group
Group type: EXPERIMENTAL
Intervention: IPH SIR
Number of subjects: 89
Study 38878969 — intervention group
Group type: EXPERIMENTAL
Intervention: IPH volume
Number of subjects: 89
Study 38878996 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive design, semi-structured intervention with quarterly leader-employee check-ins and training modules
Number of subjects: 12
Study 38878996 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 12
Study 38878996 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive design, semi-structured intervention
Number of subjects: 12